– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3)   – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif. , Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc.